3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thrombocytopenia
6
Lymphoma, Non-Hodgkin
3
Purpura, Thrombocytopenic, Idiopathic
2
Purpura, Thrombocytopenic
2
Neoplasms
2
Multiple Myeloma
2
Hodgkin Disease
2
Solid Tumor
1
Pancreatic Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
153
Fluorouracil
45
Capecitabine
45
130-nm albumin-bound paclitaxel
43
Oxaliplatin
42
Albumin-Bound Paclitaxel
39
Leucovorin
31
Erlotinib Hydrochloride
30
pembrolizumab
23
Radiotherapy
22
Irinotecan
22
Radiosurgery
20
Bevacizumab
19
Docetaxel
17
Cyclophosphamide
17
Taxes
13
Cisplatin
13
Cetuximab
13
folfirinox
12
Nivolumab
11
Surgical Procedures, Operative
7
Paclitaxel
7
Ipilimumab
7
dehydroftorafur
6
Standard of Care
6
Radiation
6
Magnetic Resonance Spectroscopy
6
spartalizumab
5
ruxolitinib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pancreatic Neoplasms
×
romiplostim
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts